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Abstract
While the essential role of bone morphogenetic protein (BMP) signaling in nervous system development is well established,
its function in the adult CNS is poorly understood. We investigated the role of BMP signaling in the adult mouse retina
following damage in vivo. Intravitreal injection of N-Methyl-D-aspartic acid (NMDA) induced extensive retinal ganglion cell
death by 2 days. During this period, BMP2, -4 and -7 were upregulated, leading to phosphorylation of the downstream
effector, Smad1/5/8 in the inner retina, including in retinal ganglion cells. Expression of Inhibitor of differentiation 1 (Id1;
a known BMP-Smad1/5/8 target) was also upregulated in the retina. This activation of BMP-Smad1/5/8 signaling was also
observed following light damage, suggesting that it is a general response to retinal injuries. Co-injection of BMP inhibitors
with NMDA effectively blocked the damage-induced BMP-Smad1/5/8 activation and led to further cell death of retinal
ganglion cells, when compared with NMDA injection alone. Moreover, treatment of the retina with exogenous BMP4 along
with NMDA damage led to a significant rescue of retinal ganglion cells. These data demonstrate that BMP-Smad1/5/8
signaling is neuroprotective for retinal ganglion cells after damage, and suggest that stimulation of this pathway can serve
as a potential target for neuroprotective therapies in retinal ganglion cell diseases, such as glaucoma.
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Introduction
Injury to the central nervous system (CNS) causes the release of
endogenous neuroprotective factors. In the retina, photoreceptors
near the site of mechanical injury are protected against light-
induced death in rat retinas [1] by the up-regulation of fibroblast
growth factor 2 (FGF2) and ciliary neurotrophic factor (CNTF)
[2,3]. Genetic models of retinal degeneration show increased
FGF2 and leukemia inhibitory factor (LIF) expression [4,5].
Although the endogenous increase in expression of these factors
provides a degree of neuroprotection, treatment of the retina with
exogenous neurotrophic factors can further potentiate neuronal
survival in retinal damage. Intravitreal delivery of LIF, CNTF,
brain-derived neurotrophic factor (BDNF), or FGF2 promotes
survival of photoreceptors after light damage or inherited retinal
degeneration, and protects retinal ganglion cells after ischemic
injury [6,7,8,9,10].
Although the neurotrophic properties of FGF2, CNTF, LIF, and
BDNFhavebeenwellstudied,bonemorphogeneticproteins(BMPs)
have received less attention. BMPs constitute a large family of
related proteins within the larger transforming growth factor beta
(TGF-beta) superfamily [11]. Canonical BMP signaling is activated
by the binding of BMPs to heterodimeric complexes of type I and
type II cell surface receptors (BMPRI and BMPRII), which in turn
leads to phosphorylation of Smad1/5/8. When phosphorylated,
Smad1/5/8formsacomplexwithSmad4,whichtranslocatestothe
nucleus to regulate target gene transcription.
BMP has important functions in early nervous system de-
velopment [12]. In addition to these developmental roles, several
studies have shown that BMP signaling increases after both acute
damage and neurodegenerative disorders. For example, BMP4
and 27 rapidly increase after spinal cord injury in rat, with
phosphorylation of Smad1/5/8 at the injury site [13,14]. In-
creased BMP6 levels have also been detected in brains of amyloid
precursor protein transgenic mice and Alzheimer’s disease patients
[15].
Although BMPs are known to play essential roles in retinal
development [16,17,18,19,20,21,22], it is not known whether the
changes in BMP signaling that occur in other regions of the CNS
also take place in damaged retinas. Therefore, we investigated
potential roles for BMP signaling after injury in mouse retina. We
find that retinal injury causes an up-regulation in BMP expression,
and Smad1/5/8 phosphorylation in the inner retina. This
activation of BMP-Smad1/5/8 signaling is neuroprotective for
retinal ganglion cells; inhibition of BMP signaling after NMDA
treatment significantly reduces the number of surviving retinal
ganglion cells. Moreover, treatment with exogenous BMP4
promotes survival of retinal ganglion cells after NMDA damage.
Thus, activation of BMP-Smad1/5/8 may provide an additional
neuroprotective target for retinal degenerations.
Materials and Methods
Mice
Mice were housed in the University of Washington Department
of Comparative Medicine and the University of Washington
Institutional Animal Care and Use Committee (UW-IACUC)
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in this study (Protocol # 2448-08). Mice used for NMDA damage
experiments were 6–8 week old C57BL/6. 6–8 week old Swiss
Webster (albino) mice were used for light damage experiments.
Hes5-GFP transgenic mice [23], which express GFP in Mu ¨ller glia
in the adult retina [24], were used for some experiments.
NMDA damage and intravitreal injection
Mice were deeply anesthetized with a single intraperitoneal
injection of ketamine (130 mg/kg) and xylazine (8.8 mg/kg). Two
differentdosesofNMDA,either10or100 mMalongwiththeother
indicated factors were delivered by a single intravitreal injection.
TheestimatedconcentrationofNMDAintheeyeaftertheinjection
was 2.8 mM for the low dose and 28 mM for the high dose.
Intravitreal injection was performed using a 32 gauge needle
(Hamilton,Reno,NV)throughthetemporallimbusoftheeye.Each
eye received 2 mL of indicated factors or PBS (vehicle control). Any
eye showing signs of damage due to intravitreal injection, such as
inflammation and morphological disruption was excluded from
analyses. Factors injected were: 25 ng/mL mouse recombinant
BMP4 (R&D systems), 1 mM dorsomorphin (Tocris), 25 ng/mL
noggin (R&D systems), and/or 0.5 mM LDN-193189 (Stemgent).
Light damage
Unanesthetized albino mice were exposed to diffuse, cool, white
fluorescent light coming from the top of the cage. Food and water
were provided ad libitum but were placed in the cage to avoid
blocking light exposure. The pupils were not dilated. Average
luminance was measured on the cage floor using a light meter, and
was approximately 10,000 lux. Mice were exposed to the light for
8 hrs (8am–4pm), and returned under normal lighting (12 hr on/
12 hr off cyclic light) for recovery before analysis.
Immunohistochemistry
Eyes were enucleated and fixed in 2% paraformaldehyde in
PBS for 45 min at room temperature immediately after animals
were euthanized with CO2. The cornea and lens were removed
during the fixation period. For cross sections, eye cups were
cryoprotected in increasing concentrations of sucrose (10–30%) in
PBS at room temperature, followed by overnight incubation at
4uC in PBS containing 30% sucrose. Eyes were embedded in
Tissue-Tek OCT Compound (Sakura Fintek, Torrance, CA),
rapidly frozen on dry ice, and then sectioned on a cryostat at 12–
14 mm. Slides were dipped in 220uC methanol briefly, dried at
room temperature, and stored at 220uC until use. For retinal
flatmounts, retinas were isolated after the fixation period, and
washed once with PBS before performing immunohistochemistry.
For immunohistochemistry, slides or retinas were washed once
with PBS containing 1% Triton X-100. Nonspecific binding was
blocked by incubating sections or retinas with 10% horse serum in
PBS for at least 1 hr at room temperature, and primary antibody
was applied overnight at 4uC. Primary antibodies used were:
rabbit anti-GFAP (Dako), goat anti-Brn3 (Santa Cruz Biotechnol-
ogy), mouse anti-HuC/D (invitrogen), rabbit anti-pSmad1/5/8,
rabbit anti-pSmad2/3 (Cell Signaling), and rabbit anti-Id1
(BioCheck). Specimens were washed, and incubated with Goat
or donkey anti-rabbit Alexa Fluor 568 (Invitrogen), goat anti-
mouse 488 (Invitrogen), or donkey anti-goat 568 (Invitrogen)
antibody for 2 hrs at room temperature. Nuclei were counter-
stained with DAPI (Sigma) and sections or retinal flatmounts were
coverslipped with PBS containing 50% glycerol. Imaging was
performed using an Olympus FluoView confocal laser scanning
microscope. To ensure quantitative image quality, laser power,
pinhole settings, PMT settings, and intensity thresholds were kept
constant for a given antibody.
Retinal ganglion cell counts
One 3-mm, single slice confocal image was taken in a 0.4 mm
2
random field for each retinal flatmount (approximately one eighth
of the whole retinal area), and the number of Brn3+ cells in each
image was counted manually. The number of Brn3+ cells in one
mm
2 of the retina was calculated and plotted. The number of
animals used for each treatment group is indicated in each figure.
Statistics were performed usinga Student’s t-test, and error bars
indicate SEM.
Real-time qPCR
The right eye of each mouse was injected with NMDA, and the
left eye was left untreated as a control. Each RNA sample was
from a single retina. Total RNA was isolated from each retina
using Trizol (Invitrogen). RNA was treated with RQ1 DNase
(Promega), and then purified with RNeasy kit (Qiagen). cDNA
synthesis was performed using iScript cDNA synthesis kit (Biorad),
and real-time qPCR was performed using SsoFast EvaGreen
Supermix (Biorad). Gapdh was used as a normalization control.
Fold change in expression was calculated for each pair of samples
(NT vs NMDA), and plotted. Statistics were performed using
a paired t-test, and error bars represents SEM. Primer sequences
used were as follows: Bmp2 F5 9-GGGACCCGCTGTCTTC-
TAGT-39, Bmp2 R5 9-TCAACTCAAATTCGCTGAGGAC-39,
Bmp4 F5 9-GACTTCGAGGCGACACTTCTA-39, Bmp4 R5 9-
GCCGGTAAAGATCCCTCATGTAA-39, Bmp5 F5 9-TTACT-
TAGGGGTATTGTGGGCT-39, Bmp5 R5 9-
CCGTCTCTCATGGTTCCGTAG-39, Bmp7 F5 9-ACGGA-
CAGGGCTTCTCCTAC-39, Bmp7 R5 9-ATGGTGGTATC-
GAGGGTGGAA-39, Gapdh F5 9-GGCATTGCTCTCAATGA-
CAA-39, and Gapdh R5 9-CTTGCTCAGTGTCCTTGCTG-39.
Western blot
Retinas were harvested immediately after animals were
euthanized by CO2 asphyxiation, and homogenized in lysis buffer
[50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1%
(v/v) NP-40, 5% (v/v) glycerol, phosphatase inhibitor cocktail
(Roche), and protease inhibitor cocktail (Sigma)]. One retina was
used per each sample. Equal amounts of total protein were
electrophoresed on 4–20% gradient SDS-polyacrylamide gels
(BioRad), and transferred to PVDF membranes (BioRad). The
membranes were blocked with 5% bovine serum albumin (BSA)
for 1 hr at room temperature, and then incubated overnight at
4uC with indicated antibodies. Antibodies used were: rabbit anti-
Id1 (Biocheck) and mouse anti-beta actin (Abcam). Membranes
were then incubated for 1 hr at room temperature with HRP-
conjugated anti-rabbit or anti-mouse secondary antibodies
(BioRad). Signals were exposed to X-ray films using SuperSignal
West Dura Extended Duration Substrate (Thermo Scientific).
Densitometry analyses were performed using ImageJ. Id1 expres-
sion was normalized to beta-actin, and plotted. Statistics were
performed using t-test, and error bars indicate SEM.
Results
Intravitreal injection of NMDA induces retinal ganglion
cell death
Previous studies have shown that intravitreal injections of
NMDA cause rapid death of retinal ganglion cells [25,26]. To
confirm these earlier studies, we made injections of high dose of
NMDA (100 mM) into the vitreal chamber of adult mice, and
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found that by 2 days after the NMDA treatment, there was
already a substantial reduction in the number of Brn3+ retinal
ganglion cells (276.5629.6 Brn3+ cells/mm
2), when compared
with uninjected (2409.56149.9 Brn3+ cells/mm
2) or PBS injected
control retinas (2277.6659.0 Brn3+ cells/mm
2) (Figure 1A–B).
There was a similar reduction in the number of another marker of
ganglion and amacrine cells, HuC/D [27], in the NMDA treated
retinas. Both Brn3 and HuC/D showed similar declines after
5 days (273.7629.6 Brn3+ cells/mm
2) (Figure 1A–B). The
reduction in the number of ganglion cells was paralleled by an
increase in the expression of GFAP, a marker for retinal damage,
in the Mu ¨ller glial cells (Figure 1A). These results indicate that
intravitreal injections of 100 mM NMDA induce rapid death of
retinal ganglion cells in adult mice.
Retinal damage activates BMP-Smad1/5/8 signaling in
the inner retina, including Mu ¨ller glia and retinal
ganglion cells
Previous studies have shown that growth factors, such as CNTF,
LIF, FGF2, and BDNF are upregulated in the retina after damage
[1,2,3,4,5]. However, there has been little characterization of
BMP signaling after retinal damage. We therefore examined
whether BMP signaling increases following NMDA-induced
retinal damage, using antibodies against activated forms of Smad,
key downstream components of the BMP and TGF-beta signaling
pathways. As shown in Figure 2A, pSmad1/5/8 is barely
detectable in the undamaged retina, but there is a substantial
increase in the labeling throughout the inner retina at 1 and 2 days
after NMDA treatment. Many of the cells in which the BMP
signaling has been activated are Mu ¨ller glia (Figure 2B), as shown
by their co-expression of pSmad 1/5/8 and Hes5-GFP [24]. The
majority of cells in the ganglion cell layer are also labeled with the
pSmad1/5/8 antibody, and these were either displaced amacrine
cells or surviving ganglion cells (Figure 2D). The activation of
Smad1/5/8 was likely to be mediated by an increased expression
of BMP ligands, BMP2, 24, and 27 in the retina following
NMDA damage (Figure 2E). Bmp4 mRNA level was increased by
2.0760.33 fold 2 days after NMDA damage compared to
untreated retinas. Smad2/3 is also activated after damage,
indicating that TGF-beta signaling is also increased after damage,
though fewer cells are labeled with pSmad2/3 than for pSmad1/
5/8. While most of the pSmad2/3 labeled cells in the INL, Hes5-
GFP+ Mu ¨ller glia were not labeled with the pSmad2/3 antibody
(Figure 2C).
To verify that the increase in BMP signaling we observe with
the pSmad1/5/8 antibody is able to activate known targets of this
pathway, we assayed Id1, a well-characterized downstream target
of BMP/Smad1/5/8 (Figure 3) [28,29]. Id1 is not detectable in
the undamaged retina, but NMDA damage induces robust
labeling of Id1 two days after the NMDA treatment. As for the
pSmad1/5/8, the Id1 expression is present in the nuclei of Hes5-
GFP+ Mu ¨ller glia (Figure 3A). The addition of either of two
different well-characterized BMP receptor inhibitors, LDN-
193189 (LDN) or dorsomorphin (DM), substantially reduced the
NMDA-induced expression of Id1 in Mu ¨ller glia. Western blot
analysis supported the results we observed in retinal sections
(Figure 3B–C). NMDA treatment caused a significant increase in
the level of Id1 in the retina (approximately 2.5 fold increase
compared to NT) (Figure 3C) and this was almost completely
blocked by co-injection of either LDN-193189 or DM.
To determine whether the activation of BMP signaling in the
inner retina after NMDA damage is specific to this type of retinal
injury, or alternatively is a more general response, we also carried
out a series of light damage experiments. Albino mice were
exposed to intense light for 8 hrs to induce rod photoreceptor loss.
As shown in Figure 4A, light damage caused an increase in
pSmad1/5/8 at both 1 and 2 days after exposure. The increase in
the number and intensity of pSmad1/5/8 labeled cells paralleled
the level of GFAP expression in the Mu ¨ller glia. As in the NMDA
damaged retinas, the pSmad1/5/8 labeled cells were found in
both the inner nuclear layer and the ganglion cell layer. There was
also a 3.3-fold increase in Id1 expression in the Mu ¨ller glia after
light damage, and this effect could be blocked by a co-injection of
DM (Figure 4B–D). The effects of light damage on Id1 expression
and its inhibition by DM were observed in sections (Figure 4B) and
by Western blot (Figure 4C–D).
Inhibitors of the BMP receptor effectively block NMDA-
induced phosphorylation of Smad1/5/8
To assess the specificity of the BMP receptor inhibitors, we
analyzed sections of retinas for pSmad1/5/8 and pSmad2/3 after
intravitreal injections of NMDA alone, BMP4 co-injection with
NMDA, or NMDA treatment with co-injection of the BMP
receptor blocker, DM and the natural BMP inhibitor, noggin
(Figure 5). In untreated retinas, there is typically a low level of
pSmad1/5/8 labeling in the ganglion cell layer (Figure 5), but cells
in the inner nuclear layer are not labeled. Either a low dose
(10 mM; Figure 5) or a high dose (100 mM; Figure 2A) of NMDA
treatment induced robust labeling of both pSmad1/5/8 and
pSmad2/3 after 2 days, particularly in cells of the inner nuclear
layer (Figure 5, arrows). Co-injection with BMP4 caused a small,
but reproducible increase in the pSmad1/5/8 labeled cells, but no
change in pSmad2/3. Co-injection of NMDA with either DM or
the combination of DM and noggin, led to a marked inhibition in
the number of pSmad1/5/8 labeled cells in the INL, but this
treatment had only a slight effect on the pSmad 2/3 labeling.
These data confirm the specificity of the BMP inhibitors for this
pathway, and also demonstrate that the combination of DM and
noggin is most effective for complete inhibition of BMP signaling
after NMDA damage.
Activation of BMP-Smad1/5/8 signaling promotes
survival of retinal ganglion cells in NMDA damage
The increase in BMP signaling in the inner retina after retinal
injury is similar to previously reported changes in other
neuroprotective growth factors, such as CNTF [2,3,4,5]. There-
fore, we assessed whether BMP could also act as a neuroprotectant
in the retina. We tested this possibility for BMP after NMDA
induced ganglion cell death (Figure 6). Mice received intravitreal
injections of mild or high doses of NMDA: 10 mM or 100 mM.
Some animals also received co-injections of BMP4, DM, or the
combination of DM and noggin. As noted above, intravitreal
injection of 100 mM NMDA caused the death of almost 90% of
the Brn3+ ganglion cells (276.5629.6 Brn3+ cells/mm
2 for
100 mM NMDA and 2409.56149.9 Brn3+ cells/mm
2 for un-
treated control) (Figure 6B). Although 10 mM NMDA injection
resulted in less damage, approximately 80% of the Brn3+ cells
were lost with the lower dose (560.8684.3 Brn3+ cells/mm
2 for
10 mM NMDA), Nevertheless, co-injection of BMP4 with either
concentration of NMDA protected ganglion cells (Figure 6 A–B).
In the higher dose of NMDA, the protection afforded by the
BMP4 was more variable (940.86398.9 Brn3+ cells/mm
2), and
did not reach statistical significance; however, the neuroprotective
effect of BMP4 was statistically significant in the 10 mM treatment
group (1107.06167.7 Brn3+ cells/mm
2) (Figure 6B).
Neuroprotective Role of BMP-Smad1/5/8 Signaling
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for ganglion cells that would otherwise die from NMDA
neurotoxicity. To determine whether the endogenous BMP-
Smad1/5/8 signaling that occurs following NMDA injury
(Figure 2, 3, 5) provides this same benefit, we co-injected BMP
inhibitors with NMDA and assessed the effects on Brn3+ ganglion
cell survival. We found that blocking endogenous BMP signaling
with the combination of DM and noggin led to a further decline in
the number of surviving ganglion cells after 10 mM NMDA
treatment (Figure 6 A–B). The number of surviving ganglion cells
in the DM/noggin treated group with 10 mM NMDA
(213.0623.1 Brn3+ cells/mm
2) was similar to that observed after
Figure 1. Intravitreal injection of NMDA results in death of retinal ganglion cells and amacrine cells by 2 days. A. Images of retinal
cross sections (left column) and flatmounts (right 3 columns) are shown. Neurotoxic damage induced by 100 mM NMDA injection caused a reduction
in Brn3+ (red) retinal ganglion cells and HuC/D+ amacrine (green) cells compared to untreated (NT) or vehicle injected (PBS) retinas by 2 days after
injection. GFAP, a marker for retinal damage, was also upregulated at 2 days. Scale bars: 100 mm. B. Brn3+ cells were counted in random flatmount
fields. At 2 days after NMDA injection, there was a significant reduction in Brn3+ cells (276.5629.6 Brn3+ cells/mm
2) compared to NT retinas
(2409.56149.9 Brn3+ cells/mm
2). No further reduction in Brn3+ cells was observed at 5d after NMDA injection (273.7629.6 Brn3+ cells/mm
2).
Therefore, we collected eyes 2 days after injection for the rest of the study. *p,0.005 with t-test.
doi:10.1371/journal.pone.0038690.g001
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2).
In the 100 mM NMDA treatment group, 10% of the Brn3+
ganglion cells were resistant to even high doses of NMDA, and
inhibition of BMP signaling has no effect on these cells. Taken
together, our results suggest that the endogenous BMP signaling
that occurs following retinal injury serves a neuroprotectant
function.
Discussion
The results of our analysis show that retinal injury, either by
NMDA treatment or by exposure to bright light, causes an increase
in BMP expression and BMP signaling in inner retinal cells. The
phosphorylation of Smad1/5/8, a key downstream component of
the BMP signaling pathway, occurs in Mu ¨ller glia and inner retinal
neurons in response to light damage or NMDA treatment. This
suggests that BMP signaling is a general response to retinal injury.
The results of experiments with BMP inhibitors indicate that
activation of BMP-Smad1/5/8 signaling after damage provides
some neuroprotective benefit to retinal ganglion cells.
BMP signaling regulates many aspects of the eye
development, including patterning, growth and
apoptosis
It has been shown that BMP2, 24 and 27 and their receptors,
BMPRs, are expressed and play essential roles during eye
development [30,31]. For example, BMP4 deficient mice
(Bmp4+/2 or 2/2) exhibit abnormal optic nerve development
and an elevated intraocular pressure, as well as failure in lens
induction and anterior segment dysgenesis [18,32]. On the other
hand, excessive BMP4 signaling leads to reduced retinal volume
and alteration of the shape of the eye [33]. The role of BMPs in
mature retina has not been extensively studied. Expression of
BMPs rapidly decreases in postnatal development and becomes
Figure 2. Retinal damage induces Smad phosphorylation in retinal ganglion cells and inner retinal cells, and increases BMP mRNA
expression in the retina. A. Injection of 100 mM NMDA induced Smad1/5/8 activation (pSmad1/5/8) in the retinal ganglion cells and inner retinal
cells. The peak of activation was observed at 2 days. Smad2/3 was also activated (pSmad2/3) in the inner retina to a lesser extent. Scale bar: 100 mm.
ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganclion cell layer. B–C. While strong Smad1/5/8 activation was induced in Hes5-GFP+ Mu ¨ller
glia (green) 2 days after NMDA injection (B), Smad2/3 activation was observed in Hes5-GFP- cells in the INL (C). Scale bars: 30 mm. D. NMDA damage
activated Smad1/5/8 in remaining retinal ganglion cells and displaced amacrine cells located in the GCL. Scale bars: 10 mm. E. Real-time qPCR data
showing that NMDA damage induced significant increase in Bmp4 expression in the retina 2 days after NMDA damage. Expression of other ligands of
BMP signaling, Bmp2 and 27, was also induced. *p,0.05 with paired t-test (n=4). Images shown in A–D are representative of at least 3 animals per
each treatment group.
doi:10.1371/journal.pone.0038690.g002
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expression of Bmpr1b in adult retina [17,30]. Moreover, both
BmprIb and BmprII mRNAs are expressed in the inner nuclear and
ganglion cell layers at least as late as postnatal day 10 in mouse
retina [19], suggesting that adult retinal cells can activate BMP
signaling when ligands are available. Our data supports this since
retinal damage or injection of BMP4 can readily activate Smad
signaling (Figures 2A and 5).
Previous studies have established a role for BMP signaling in
regulating apoptosis during retinal development: in cultured chick
embryonic eyes or retinas, exogenous application of BMP4 or 27
promoted apoptosis [17,22]; this pro-apoptotic effect of BMPs was
significantlyreducedbytreatmentwithBMPinhibitor,noggin[22].
Treatment of postnatal day 2 mouse retinal whole mounts with
BMP4 also induced increased apoptosis, especially in retinal
ganglion cell layer [17]. By contrast, an anti-apoptotic role of
BMP signaling in developing mouse retina has been shown in vivo.
Bmpr1b2/2 mice display increased apoptosis in the inner retina at
postnatal day 7 [19]. In addition, conditional ablation of Smad4,
required for canonical BMP signaling, resulted in increased
apoptosis in the embryonic retina [20]. In posthatch chicks,
intraocular BMP injections also dramatically reduced the number
of apoptotic cells induced by NMDA injections [34]. In this report,
we demonstrate that activation of BMP signaling during neurotoxic
damage in adult mouse retina promotes survival of retinal ganglion
cells in vivo (Figure 6). The downstream mechanisms by which BMP
regulates the apopotic pathway are likely to be complex, since it can
have both positive and negative effects on cell survival.
Activation of BMP-Smad1/5/8 signaling may be
neuroprotective after adult CNS injury
In other regions of adult CNS, BMPs are known to be
upregulated following injury. Rapid increases in BMP4 and 27
expression and phosphorylation of Smad1/5/8 were observed at
the site of demyelinating lesions in rat spinal cord, which may
stimulate glial scar formation [13]. BMP7 expression was in-
creased dramatically in both glial cells and motor neurons in
a different spinal cord injury model [14]. In addition, an increase
in BMPRII expression was observed in the rat hippocampus after
ischemia [35]. It has been shown that treatment with exogenous
BMP7 prior to induction of ischemia-induced injury or focal stroke
leads to reduction in cerebral infraction and promotes functional
Figure 3. NMDA damage induces expression of Id1, a known target of BMP-Smad1/5/8 signaling. A. Representative images from at least
3 animals per treatment are shown. Injection of 100 mM NMDA induced Id1 expression (red) in Hes5-GFP+ Mu ¨ller cells (green). Id1 expression was
blocked by coinjection of BMP inhibitors, LDN-193189 (LDN) or dorsomorphin (DM). Scale bar: 50 mm. B. Representative Western blot showing the
level of Id1 expression 2 days after injection of the indicated factors. C. Quantification of the Western blots. More than a 2 fold increase in Id1
expression was observed after NMDA damage, and this increase was blocked effectively by LDN or DM. The level of Id1 expression was normalized to
beta-actin. *p,0.05 (t-test; n=3 retinas).
doi:10.1371/journal.pone.0038690.g003
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spinal cord injury have also been demonstrated [38]. These studies
suggest a role for BMPs in promoting cell survival in the adult
CNS. In this study, we demonstrated that activation of BMP
signaling following retinal damage promotes retinal ganglion cell
survival in vivo, further supporting a neuroprotective role for BMP
signaling in the CNS.
Potential mechanisms of BMP-mediated protection of
retinal ganglion cell after damage
It is currently unclear whether the neuroprotective effect of
BMP signaling on retinal ganglion cells is due to a direct effect or
mediated via Mu ¨ller glial activation. Treatment of the retina with
BMP inhibitors, DM and noggin, along with 10 mM NMDA
damage sufficiently blocked Smad1/5/8 activation in both cell
types (Figure 5), while increasing sensitivity of retinal ganglion cells
to neurotoxic damage (Figure 6).
Figure 4. BMP-Smad1/5/8 signaling is activated in the retina after light damage. A. Exposure to bright light (light damage; LD) is known to
induce a significant loss of photoreceptor cells in the ONL. Two days after 8 hrs of LD, there was strong increase in GFAP expression, suggesting the
retina was under stress. Smad1/5/8 activation (pSmad 1/5/8) was also observed in retinal ganglion cells and cells in the INL. ONL, outer nuclear layer;
INL, inner nuclear layer; GCL, ganclion cell layer. Scale bars: 50 mm. B. 8 hrs of LD induced Id1 expression and this was blocked by injection of the BMP
inhibitor, DM. Scale bar: 50 mm. C. Representative Western blot showing the level of Id1 expression after the indicated treatments. D. Id1 expression
was induced by LD (3.3 fold increase compared to NT), and the expression was effectively blocked by injection of DM along with LD. The level of Id1
expression was normalized to beta-actin. Y axis shows an arbitrary value. *p,0.05 (t-test; n= at least 3 retinas per treatment). Images shown in A and
B are representative of at least 3 animals per each treatment group.
doi:10.1371/journal.pone.0038690.g004
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gliosis that forms the glial scar after spinal cord injuries in adult
animals. Expression of BMP2, 24 and 27 is induced and Smad1/
5/8 is activated after spinal cord injury [13,14,39]. This activation
of BMP signaling leads to reactive gliosis and scar formation,
possibly through the complex regulation of GFAP expression
[39,40]. Conditional deletions of Bmpr1a and Bmpr1b in astrocytes
show that these receptors have opposite effects on the formation of
glial scar: loss of Bmpr1a leads to a reduction in glial hypertrophy,
whereas loss of Bmpr1b leads to hyper-reactive astrocytes [40].
Soon after retinal damage, Mu ¨ller glia upregulate GFAP [41] and
release neurotrophic factors to prevent further tissue damage
[42,43,44]. In our NMDA and light damage models, strong GFAP
expression was induced (Figures 1 and 4A) when BMP-Smad1/5/
8 signaling is most active (Figures 2A and 4A). Moreover, we
observed that damage induced expression of Id1, a known BMP-
Smad1/5/8 target (Figures 3A and 4B). BMP-Smad1/5/8
signaling may have a role in regulating Mu ¨ller cell reactivity and
release of neurotrophic factors, which in turn indirectly promotes
ganglion cell survival in retinal damage. This hypothesis is
consistent with a previous report in posthatch chick, which found
that intraocular injection of BMP prior to NMDA treatment
prevented the proliferative Muller glial response that occurs
following NMDA damage [34].
ItisalsopossiblethatBMPinteractswithothersignalingfactorsto
promote ganglion cell survival. The neuroprotective effects of the
members of IL-6 family of cytokines, such as CNTF and LIF, are
well characterized [45,46,47,48,49]. Treatment with CNTF
promotes survival of injured retinal ganglion cell in vivo
[50,51,52,53,54]. There is evidence that in neural progenitors,
LIFand BMP2actsynergistically toinduce astrocytedifferentiation
through forming a complex between STAT3 and Smad1 [55]. A
study by Fukuda et al has shown that LIF stimulates BMP2
expression in STAT3-dependent manner, which further induced
Smad1activationinneuroepithelialcells[56].Asimilarmechanism
might exist in the mature retina, since injury to the retina leads to
both CNTF/LIF upregulation and glial reactivity. Further studies
will determine the mechanisms of BMP-induced neuroprotection.
BMP-Smad1/5/8 signaling may serve as a potential target
for neuroprotective therapies
There is a great demand for the development of neuroprotective
therapies for retinal degenerations caused by ganglion cell death,
such as glaucoma, given that currently available treatments are
inadequate. As we demonstrated here, BMP agonists can be
potential neuroprotective agents that delay or prevent ganglion
cell death in pathogenic conditions. Several neurotrophic factors
have been implicated in retinal ganglion cell damage and their
survival; intravitreal injection of CNTF, BDNF, or FGF2 all show
some degree of ganglion cell protection after ischemic injury in rat
retina [10]. Retinal ganglion cell axotomy induces BDNF
expression in the frog retina, and its expression further increases
with FGF2 treatment [57]. This FGF2-induced BDNF upregula-
tion is important for the long-term survival of retinal ganglion cells
[58]. Combining BMPs and these other known protective factors
may be useful in enhancing their survival effects on retinal
ganglion cells, as they potentially activate several different
neuroprotective pathways. For example, the protective effects of
neurotrophins (NGF, BFNF, NT3 and 24) are enhanced by co-
treatment with BMP6 or 27 in stressed septal cholinergic neurons
in vitro [59]. Similar protective effects may be obtained by
Figure 5. Injection of BMP4 or inhibitors of BMP along with NMDA potentiates or decreases, respectively, Smad1/5/8 activation
without affecting Smad2/3 signaling. Smad1/5/8 and Smad2/3 activation was detected 2 days after the injection of indicated factors by
immunohistochemistry. A lower dose of NMDA (10 mM) sufficiently activates both Smad1/5/8 and Smad2/3 in the inner retina. Injection of BMP4
along with NMDA caused a small increase in pSmad1/5/8 over the NMDA alone. When NMDA was co-injected with DM, Smad1/5/8 phosphorylation
was blocked effectively without affecting Smad2/3 activation. Co-injection with an additional BMP signaling inhibitor, noggin (Nog), completely
blocked Smad1/5/8 activation, and caused slight reduction in pSmad2/3. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganclion cell layer.
Scale bars: 30 mm. Representative images from at least 3 animals per treatment are shown.
doi:10.1371/journal.pone.0038690.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38690treatment of damaged retinal ganglion cells with BMPs in
combination with other neuroprotective factors.
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Figure 6. BMP-Smad1/5/8 signaling promotes survival of retinal ganglion cells in vivo after NMDA damage. A. Retinas were collected
2 days after NMDA injection (10 mM or 100 mM) with or without indicated factors, and then immunostained for Brn3, a marker for retinal ganglion
cells. Representative images of retinal flatmouts are shown. Scale bar: 100 mm. B. Brn3+ cells were counted in random flatmount fields. In 10 mM
NMDA damage, there were significantly more Brn3+ cells when BMP4 was co-injected with NMDA. On the other hand, co-injection of BMP inhibitors
(NMDA+DM+Noggin) showed a significant reduction in Brn3+ cells compared to NMDA injection alone. The same trend was observed for the more
severe NMDA damage (100 mM). *p,0.01 (t-test). Number of retinas analyzed for each treatment is shown in B.
doi:10.1371/journal.pone.0038690.g006
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